Disease-modifying antirheumatic drug — Competitive Intelligence Brief

Disease-modifying antirheumatic drug (Disease-modifying antirheumatic drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Disease-modifying antirheumatic drug (DMARD). Area: Immunology / Rheumatology.

phase 3 Disease-modifying antirheumatic drug (DMARD) Immunology / Rheumatology Small molecule

Target snapshot

Disease-modifying antirheumatic drug (Disease-modifying antirheumatic drug) — Pfizer. Disease-modifying antirheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Disease-modifying antirheumatic drug TARGET	Disease-modifying antirheumatic drug	Pfizer	phase 3	Disease-modifying antirheumatic drug (DMARD)
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)
Methotrexate plus sulfasalazine	Methotrexate plus sulfasalazine	Singapore General Hospital	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Multiple (dihydrofolate reductase, folate metabolism; sulfapyridine and 5-ASA mechanisms)
Leflunomide plus Methotrexate	Leflunomide plus Methotrexate	Bangladesh Medical University	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Dihydroorotate dehydrogenase (leflunomide); Dihydrofolate reductase (methotrexate)
Methotrexate-Sulfasalazine-Hydroxychloroquine	Methotrexate-Sulfasalazine-Hydroxychloroquine	University of Nebraska	phase 3	Disease-modifying antirheumatic drug (DMARD) combination
Leflunomide-Sulfasalazine-Hydroxychloroquine	Leflunomide-Sulfasalazine-Hydroxychloroquine	University of Nebraska	phase 3	Disease-modifying antirheumatic drug (DMARD) combination	Multiple targets: dihydroorotate dehydrogenase (leflunomide), NF-κB pathway (sulfasalazine), lysosomal function and TLR signaling (hydroxychloroquine)
Methotrexate, Hydroxychloroquine	Methotrexate, Hydroxychloroquine	Sanjay Gandhi Postgraduate Institute of Medical Sciences	phase 3	Immunosuppressive/Disease-modifying antirheumatic drug (DMARD) combination	Dihydrofolate reductase (methotrexate); Toll-like receptors and lysosomal pH (hydroxychloroquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Disease-modifying antirheumatic drug (DMARD) class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Pfizer · 1 drug in this class